Jyong Biotech Ltd. · NASDAQ:MENS
Jyong Biotech — IPO Roadshow (March 2025)
35 slides from Jyong Biotech's IPO roadshow presentation, Mar 27, 2025
Slide 1: Jyong Biotech Ltd. Issuer Free Writing Prospectus
Jyong Biotech Ltd. March 2025 Issuer Free Writing Prospectus dated March 27, 2025 Filed pursuant to Rule 433 of the Securities Act of 1933, as amended Relating to Preliminary Prospectus dated March 11, 2025 Registration No. 333 - 277725
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Jyong Biotech Ltd . (the “Company”) solely for informational purposes . The information included herein in this presentation has not been independently verified . By viewing or accessing the information contained in this presentation, you acknowledge
Slide 3: Preliminary Offering Summary
Preliminary Offering Summary Jyong Biotech Ltd. | Page 3 • Jyong Biotech Ltd. Issuer • Nasdaq Global Market/ MENS Listing / Ticker • Initial Public Offering (In Progress) Offering Type • 2,666,667 o rdinary shares (before exercising over - allotment option ） Shares Offered • 400,000 ordinary shares
Slide 4: Table of contents
Table of contents 01 04 02 05 03 06 Company Overview - Core Products section Industry Overview – Potential market section Investment Highlights section Growth Strategies section Financials section Appendix section Jyong Biotech Ltd. | Page 4
Slide 5: Company Overview - Core Products
Company Overview - Core Products 01 Jyong Biotech Ltd. | Page 5
Slide 6: We Are a Science-Driven Biotech Company Based in Taiwan
• Specialize in the treatment of urinary system diseases • Committed to developing and commercializing innovative and differentiated new drugs • Focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China) We Are a Science - Driven Biotech Company Based in Taiwan Company O
Slide 7: Core Drug Candidate Pipeline
Core Drug Candidate Pipeline Jyong Biotech Ltd. | Page 7 Company Overview Industry Overview Investment Highlights Growth Strategies Financials IC • IC is also an important drug candidate that utilizes nanocarriers to enhance bioavailability for intravenous and intravesical administration. • It is as
Slide 8: Validated R&D Capabilities and Proprietary Platform
Validated R&D Capabilities and Propietary Platform Healthy pipeline of drug candidates at clinical stage and preclinical stage Treatment for: • Benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS) • Prostate cancer prevention • Interstitial cystitis • Early - stage drug discovery and
Slide 9: In-house Capabilities to Manufacture Drug Candidates
Company Overview Industry Overview Investment Highlights Growth Strategies Financials Jyong Biotech Ltd. | Page 9 In - house Capabilities to Manufacture Drug Candidates • Yilan Letzer Pharmaceutical Factory authorized by TFDA to conduct drug manufacturing, packaging, laboratory operations, transport
Slide 10: Industry Overview – Potential market for MCS-2
Industry Overview – Potential market for MCS - 2 02 Jyong Biotech Ltd. | Page 10
Slide 11: Addressable Market Potentials
• The world's growing and aging population is driving increased healthcare demand and expenditure • The aging population reached 747.5 million in 2021, a 15.0% increase from 2017. People over 55 years old totalled 14,374.6 million in 2020, growing at 2.3% annually • Global healthcare expenditure is
Slide 12: Global BPH Drugs Market
• Global BPH prevalence rose from 88.4 million in 2017 to 94.2 million in 2020, a 6.5% increase • BPH drugs market grew from $3.7 billion in 2017 to $4.1 billion in 2020, projected to reach $9.8 billion in 2026 • Factors driving market growth include aging population, rising obesity rates, and incre
Slide 13: Global PCP Drugs Market
Company Overview Industry Overview Investment Highlights Growth Strategies Financials Jyong Biotech Ltd. | Page 13 Source: Frost & Sullivan Global PCP Drugs Market - Prevalence increased from 10.0 million (2017) to 11.2 million (2020) globally (3.9% CAGR) - Market size: $12.6 billion (2019), project
Slide 14: Market Drivers, Future Trends and Entry Barriers
1. Shift from marketing - focused to value - focused: p harma companies must prioritize R&D and innovation over excessive marketing expenses to drive industry growth 2. Increasing demand for botanical drugs: natural product trends will boost the need for plant - derived medications, but ensuring con
Slide 15: Investment Highlights
Investment Highlights 03 Jyong Biotech Ltd. | Page 15
Slide 16: Innovative Plant-Derived New Drug Candidate for BPH/LUTS
MCS - 2 (BPH/LUTS Treatment) • BPH/LUTS is a common urinary tract disease in middle - aged men. Currently, there are several drugs to treat BPH/LUTS, however, only about 60 - 70 percent of patents treated can have symptom improved. Therefore, current BPH/LUTS treatments have unmet medical needs on e
Slide 17: Safety Issues: Current BPH/LUTS Adverse Effects
Safety Issues: Current BPH/LUTS Adverse Effects Manufacturer Chemical Name Pharmacologic Class Orthostatic hypotension, ejaculation disorder, n asal congestion, malaise, syncope, tachycardia, nausea, indigestion/gastralgia, diarrhea. Astellas Pharma (Japan) T amsulosin alpha - 1 adrenergic blockers
Slide 18: Phase III Clinical Trials
Phase III Clinical Trials * US Total Placebo MCS - 2 (API - 1) 30 mg/day MCS - 2 (API - 1) 15 mg/day N=274 N (%) N=76 N (%) N=156 N (%) N=42 N (%) 108 (39.4) 33 (43.4) 59 (37.8) 16 (38.1) Adverse Event (AE) 41 (15.0) 14 (18.4) 21 (13.5) 6 (14.3) Related AE 3 (1.1) 2 (2.6) 1 (0.6) 0 (0.0) Serious Adv
Slide 19: Diverse Drug Portfolio And Validated R&D Capabilities
Company Overview Industry Overview Investment Highlights Growth Strategies Financials MCS - 2 Invention patents Trademarks 31 invention patents in 19 territories. 58 trademarks in more than 46 territories. Innovative Proprietary R&D Platform Discovery, Research and Development R&D Center Spans a Gro
Slide 20: Key Issued Invention Patents in Multiple Territories
Company Overview Industry Overview Investment Highlights Growth Strategies Financials Key Issued Invention Patents in Multiple Territories Expiration date of patent right Country ( Owned Patent number) Patent* ~2034/12 Taiwan Invention ~2034/12 South Korean Invention ~2034/12 Singapore Invention ~20
Slide 21: Integrated In-house Capabilities for Pharmaceutical Innovation
Jyong Biotech Ltd. | Page 21 Integrated In - house Capabilities That Well Position Us For Pharmaceutical Innovation From Bench To Bedside Company Overview Industry Overview Investment Highlights Growth Strategies Financials Our lead candidate, MCS - 2, is a plant - derived drug specifically designed
Slide 22: Highly Experienced Management Leads R&D
Company Overview Industry Overview Investment Highlights Growth Strategies Financials Jyong Biotech Ltd. | Page 22 Highly Experienced Management Leads R&D Fu - Feng Kuo - Director since December 2018 - Chairwoman of the board of directors and CEO - Founder of Health Ever Bio - Tech Co., Ltd. - Chair
Slide 23: Management Team with Great Vision
Company Overview Industry Overview Investment Highlights Growth Strategies Financials Jyong Biotech Ltd. | Page 23 Management Team with Great Vision Alfred Ying - Over 20 years of capital markets experience - Expertise in corporate finance, capital raising, finance, and accounting - Currently CFO of
Slide 24: Board Directors
Company Overview Industry Overview Investment Highlights Growth Strategies Financials Jyong Biotech Ltd. | Page 24 Board Directors Hung - Shu Fan - Professor and associate dean at Fu Jen Catholic University - Independent director of Taiwan Semiconductor Co., Ltd. and Tigerair Taiwan Co., Ltd. - Form
Slide 25: Growth Strategies
Growth Strategies 04 Jyong Biotech Ltd. | Page 25
Slide 26: MCS-2 Commercialization
◎ Dedicated sales and marketing team for pipeline drug candidates, including MCS - 2 ◎ Experienced team in Taiwan, seeking local pharmaceutical partnerships in other territories ◎ Senior product manager leading MCS - 2 strategies ◎ Positive feedback from U.S. survey among urologists and payers ◎ Phy
Slide 27: Advance Development for Other Drug Candidates
Company Overview Industry Overview Investment Highlights Growth Strategies Financials Jyong Biotech Ltd. | Page 27 Deepen pipeline in existing therapeutic areas with new drugs • Anchor therapeutic focus areas with competitive drug products and expand around them • Foster talent growth and recruit hi
Slide 28: Build Commercial Infrastructure
Jyong Biotech Ltd. | Page 28 Build Commercial Infrastructure Company Overview Industry Overview Investment Highlights Growth Strategies Financials ◎ Maximize patient reach for future products, specifically MCS - 2 ◎ Establish dedicated salesforce in the U.S., EU, and Asia (Taiwan and mainland China)
Slide 29: Financials
Financials 05 Jyong Biotech Ltd. | Page 29
Slide 30: Selected Financial Information (Unaudited)
Jyong Biotech Ltd. | Page 30 Company Overview Industry Overview Investment Highlights Growth Strategies Financials Selected Financial Information (Unaudited) $1,109 $951 Half Year Ended 06/2023 Half Year Ended 06/2024 Total Operating Expenses USD Thousand $1,718 $99 Half Year Ended 06/2023 Half Year
Slide 31: Research and Development Expenses
Jyong Biotech Ltd. | Page 31 Company Overview Industry Overview Investment Highlights Growth Strategies Financials Research and Development Expenses ◎ This table sets forth a breakdown of the major components of our research and development expenses in absolute amounts and as a percentage of our tot
Slide 32: Unaudited Interim Condensed Consolidated Balance Sheets
APPENDIX – UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (in thousand US$) As of June 30, 2024 As of December 31, 2023 Unaudited Audited ASSETS Current Assets 96 $ 177 $ Cash 3 1,565 Restricted cash 101 97 Prepayments and other current assets 200 1,839 Total current assets 6,240 6,409 Tota
Slide 33: Unaudited Interim Statements of Operations and Comprehensive Loss
APPENDIX – UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousand US$) For the six months ended June 30, 2024 2023 Unaudited Unaudited Operating expenses ) (499 $ ) (538 $ Research and development ) (21 ) (22 Selling and marketing ) (431 ) (549 General
Slide 34: Unaudited Interim Statements of Cash Flows
APPENDIX – UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousand US$) For the six months ended June 30, 2024 2023 Unaudited Unaudited Cash flows from operating activities ) (1,326 $ ) (1,742 $ Net loss ) (2,773 ) (1,292 Net cash used in operating activities Cash flows from i
Slide 35: Thanks
Company Jyong Biotech Ltd. services@hebiotech.com +886 (2) 2732 5205 www.healtheverbiotech.com Thanks Underwriter Joseph Stone Capital, LLC 585 Stewart Avenue, Unit L60 - C Garden City, New York 11530 Tel: 888 - 302 - 5548 Email: corporatefinance@Josephstonecapital.com ccao@josephstonecapital.com